Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pre-operative Endocrine Therapy

Pre-operative Endocrine Therapy Curr Breast Cancer Rep (2017) 9:202–209 https://doi.org/10.1007/s12609-017-0255-6 SYSTEMIC THERAPIES (M LIU AND T HADDAD, SECTION EDITORS) 1 1 2 1 Laura M. Arthur & Arran K. Turnbull & Lucy R. Khan & J. Michael Dixon Published online: 27 October 2017 The Author(s) 2017. This article is an open access publication . . . Abstract Keywords Breast cancer Neoadjuvant Endocrine therapy . . Purpose of Review Pre-operative endocrine therapy can be Aromatase inhibitor Pre-operative Tamoxifen used to down-stage large or locally advanced breast cancers in ER+ disease. In the last four decades, it has evolved from a treatment perceived as an alternative to surgery for those too Introduction unfit to undergo surgery or chemotherapy, to the present day where it is a valuable and valid option in the treatment of Approximately 75% of all invasive breast cancers express postmenopausal women with ER-rich (Allred score 7–8, or oestrogen receptor alpha (ER+), a favourable prognostic > 50% staining for ER) breast cancer. factor and a strong predictor of response to endocrine Recent Findings Emerging data from the metastatic setting is therapies. In early breast cancer, treatment usually in- translating into neoadjuvant trials, utilising dual endocrine cludes surgery, followed by adjuvant (post-operative) targeting http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Pre-operative Endocrine Therapy

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/pre-operative-endocrine-therapy-DaJpjhmyk0

References (58)

Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-017-0255-6
Publisher site
See Article on Publisher Site

Abstract

Curr Breast Cancer Rep (2017) 9:202–209 https://doi.org/10.1007/s12609-017-0255-6 SYSTEMIC THERAPIES (M LIU AND T HADDAD, SECTION EDITORS) 1 1 2 1 Laura M. Arthur & Arran K. Turnbull & Lucy R. Khan & J. Michael Dixon Published online: 27 October 2017 The Author(s) 2017. This article is an open access publication . . . Abstract Keywords Breast cancer Neoadjuvant Endocrine therapy . . Purpose of Review Pre-operative endocrine therapy can be Aromatase inhibitor Pre-operative Tamoxifen used to down-stage large or locally advanced breast cancers in ER+ disease. In the last four decades, it has evolved from a treatment perceived as an alternative to surgery for those too Introduction unfit to undergo surgery or chemotherapy, to the present day where it is a valuable and valid option in the treatment of Approximately 75% of all invasive breast cancers express postmenopausal women with ER-rich (Allred score 7–8, or oestrogen receptor alpha (ER+), a favourable prognostic > 50% staining for ER) breast cancer. factor and a strong predictor of response to endocrine Recent Findings Emerging data from the metastatic setting is therapies. In early breast cancer, treatment usually in- translating into neoadjuvant trials, utilising dual endocrine cludes surgery, followed by adjuvant (post-operative) targeting

Journal

Current Breast Cancer Reports – Springer Journals

Published: Oct 27, 2017

There are no references for this article.